Roche Pharmaceutical Development and Sales Overview
Pharma Division sales YTD Sep 2022
Top 20 products
Roche
Global
US
CHFM
% CER
CHFM
% CER
CHFM
Europe
% CER
Japan
International
CHFM
% CER
CHFM % CER
Ocrevus
4,427
17
3,283
13
808
25
336
37
Perjeta
3,090
5
1,135
1
661
-16
175
-1
1,119
33
Hemlibra
2,778
28
1,684
22
542
32
277
20
275
76
Tecentriq
2,692
10
1,451
9
573
19
326
-5
342
16
Actemra/RoActemra
2,039
-23
914
-33
602
-3
256
1
267
-39
Herceptin
1,672
-18
376
-28
329
-13
40
-28
927
-15
Avastin
1,652
-29
497
-36
158
-51
378
-15
619
-21
Xolair
1,625
10
1,625
10
MabThera
1,596 -20
1,002
-20
Kadcyla
1,590
11
619
-3
Alecensa
1,127
16
331
TNKase/Activase
881
-8
836
Lucentis
800
-25
800
-25
Evrysdi
793
101
348
2922
20
5828
156
-18
24
-10
414
508
8
101
21
218
6
169
5
409
-9
¥8
-23
362
5520
50
26
45
5
24
253
335
*
60
132
Ronapreve
631
-36
102
-81
452
42
77
៦៩
100
-49
Esbriet
Gazyva
590
-25
381
-34
186
-1
23
-22
539
8
251
3
144
-7
39
-7
105
89
Phesgo
Pulmozyme
CellCept
Pharma Division
526
150
217
112
263
204
46
99
414
-1
280
2
73
-12
61
-2
386
-12
30
-19
101
-6
43
-6
212
-14
33,189
0
17,199
-1
6,100
-1
3,029
7
6,861
0
CER = Constant Exchange Rates (avg. full year 2021); *over 500%
146View entire presentation